[go: up one dir, main page]

AR054251A1 - Vacuna de toxoide de c. perfringens alfa - Google Patents

Vacuna de toxoide de c. perfringens alfa

Info

Publication number
AR054251A1
AR054251A1 AR20060101501A ARP060101501A AR054251A1 AR 054251 A1 AR054251 A1 AR 054251A1 AR 20060101501 A AR20060101501 A AR 20060101501A AR P060101501 A ARP060101501 A AR P060101501A AR 054251 A1 AR054251 A1 AR 054251A1
Authority
AR
Argentina
Prior art keywords
perfringens
alfa
vaccines
toxoid vaccine
type
Prior art date
Application number
AR20060101501A
Other languages
English (en)
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36820082&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR054251(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of AR054251A1 publication Critical patent/AR054251A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente describe vacunas que comprenden toxoides de C. perfringens alfa de un Tipo, sus fragmentos antigénicos, fragmentos antigénicos inactivos de toxinas alfa de un Tipo de C. perfringens, o cualquiera de sus combinaciones. La presente además describe métodos para el uso de estas vacunas en la proteccion de animales contra enfermedades clostridiales. La presente describe también métodos para la elaboracion de estas vacunas.
AR20060101501A 2005-04-18 2006-04-17 Vacuna de toxoide de c. perfringens alfa AR054251A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67228905P 2005-04-18 2005-04-18

Publications (1)

Publication Number Publication Date
AR054251A1 true AR054251A1 (es) 2007-06-13

Family

ID=36820082

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20060101501A AR054251A1 (es) 2005-04-18 2006-04-17 Vacuna de toxoide de c. perfringens alfa

Country Status (25)

Country Link
US (2) US8980283B2 (es)
EP (1) EP1874344B1 (es)
JP (2) JP5243951B2 (es)
KR (1) KR20080005277A (es)
CN (1) CN101198352B (es)
AR (1) AR054251A1 (es)
AU (1) AU2006236365B2 (es)
BR (1) BRPI0610843B1 (es)
CA (1) CA2606180C (es)
CR (1) CR9443A (es)
DK (1) DK1874344T3 (es)
ES (1) ES2583484T3 (es)
IL (1) IL186701A0 (es)
MA (1) MA29406B1 (es)
MX (1) MX2007013053A (es)
MY (1) MY149604A (es)
NZ (1) NZ562637A (es)
PE (1) PE20061398A1 (es)
RU (1) RU2434638C2 (es)
SG (1) SG186672A1 (es)
TN (1) TNSN07387A1 (es)
TW (1) TWI311057B (es)
UA (1) UA98099C2 (es)
WO (1) WO2006113772A1 (es)
ZA (1) ZA200709516B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY149604A (en) * 2005-04-18 2013-09-13 Schering Plough Ltd C.perfringens alpha toxoid vaccine
RU2409385C2 (ru) * 2006-03-30 2011-01-20 Эмбрекс, Инк. Способ иммунизации птицы против инфекции, вызванной бактериями clostridium
RU2593945C2 (ru) * 2006-04-17 2016-08-10 Интервет Интернэшнл Б.В., ПО СУЩЕСТВУ НЕТОКСИЧНЫЙ МУТЕИН АЛЬФА-ТОКСИНА Clostridium perfringens И КОДИРУЮЩАЯ ЕГО МОЛЕКУЛА НУКЛЕИНОВОЙ КИСЛОТЫ
CA2667255A1 (en) 2006-10-27 2008-05-08 Dow Agrosciences Llc Poultry vaccine, for necrotic enteritis, comprising a mutated clostridium perfringens alpha toxin antigen, and methods of producing the vaccine
MX2009005117A (es) * 2006-11-20 2009-05-27 Intervet Int Bv Uso de bacteria clostridium perfringens de tipo c para la elaboracion de una vacuna.
CA2629790C (en) * 2007-04-12 2015-06-30 Nutratech Use of avian anti-methanogen antibodies for reduction of methane production
WO2009000066A1 (en) * 2007-06-22 2008-12-31 University Of Guelph Vaccine against clostridium perfringens
WO2009076668A2 (en) * 2007-12-13 2009-06-18 Alpharma, Inc. Bacteriophage preparations and method of use thereof
US8293100B2 (en) 2009-03-13 2012-10-23 Terrasep, Llc Methods and apparatus for centrifugal liquid chromatography
US8916162B2 (en) 2010-02-20 2014-12-23 Alexey Gennadievich Zdanovsky Botulinum neurotoxin antigenic compositions and methods
WO2011151941A1 (ja) * 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
CN102008720B (zh) * 2010-07-20 2015-02-25 东北农业大学 抗魏氏梭菌病转基因植物疫苗及其制作方法
EP2793934B1 (en) * 2011-12-23 2017-08-23 Merz Pharma GmbH & Co. KGaA Novel method for the manufacturing of di-chain proteins for use in humans
CN102657683B (zh) * 2012-06-02 2014-05-07 哈尔滨工业大学 一种免疫类毒素的制备方法
CN102698259B (zh) * 2012-06-12 2017-02-08 北京中海生物科技有限公司 一种鸡坏死性肠炎（a型）灭活疫苗制备方法
CN102688484B (zh) * 2012-06-13 2016-03-30 北京中海生物科技有限公司 一种鸡坏死性肠炎（c型）灭活疫苗的生产方法
EP2911688B1 (en) 2012-10-26 2019-10-16 Intervet International B.V. Cross-protecting salmonella vaccines
CN103463632B (zh) * 2013-09-05 2016-01-06 山东农业大学 牛羊肠毒血症的d型产气荚膜梭菌类毒素疫苗的制备方法
FR3012964A1 (fr) * 2013-11-12 2015-05-15 Seppic Sa Vaccins adjuves pour vaccination aviaire in ovo
CN103861094A (zh) * 2014-03-27 2014-06-18 山东农业大学 一种产气荚膜梭菌α毒素基因工程疫苗及其应用
CN104131022A (zh) * 2014-08-01 2014-11-05 中国农业科学院兰州兽医研究所 产气荚膜梭菌α、β1、β2、ε毒素共表达载体及其构建方法和表达方法
CN104531731B (zh) * 2014-12-15 2018-06-26 中国人民解放军军事医学科学院军事兽医研究所 产气荚膜梭菌α毒素人源化单链抗体7D
CN104531730B (zh) * 2014-12-15 2018-07-17 中国人民解放军军事医学科学院军事兽医研究所 产气荚膜梭菌α毒素人源化单链抗体8B
CN104531867B (zh) * 2014-12-25 2017-03-29 湖北省农业科学院畜牧兽医研究所 产气荚膜梭菌肠毒素阳性菌双重荧光定量pcr快速检测试剂盒
EP3112474A1 (en) * 2015-06-29 2017-01-04 Evonik Degussa GmbH Method of detecting avian necrotic enteritis
MA47317A (fr) 2017-01-23 2019-11-27 Univ Florida Induction d'immunité protectrice contre des antigènes
WO2018159476A1 (ja) * 2017-02-28 2018-09-07 一般財団法人阪大微生物病研究会 多価ワクチン
EP3630800A4 (en) * 2017-05-31 2021-03-24 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food VACCINE AGAINST NECROTIC ENTERITIS IN POULTRY
EP3634480A1 (en) 2017-06-09 2020-04-15 Hipra Scientific, S.L.U. Vaccine comprising clostridium toxoids
BR112020002374A2 (pt) 2017-08-04 2020-09-08 University Of Florida Research Foundation, Incorporated indução de imunidade protetora contra antígenos
CN107596361B (zh) * 2017-09-12 2020-08-14 浙江海隆生物科技有限公司 牛a型产气荚膜梭菌的亚单位疫苗及其制备方法和应用
CN107875377B (zh) * 2017-11-06 2020-01-03 山东农业大学 一种e型产气荚膜梭菌类毒素疫苗的制备方法
CN109954135B (zh) * 2017-12-25 2023-01-31 金宇保灵生物药品有限公司 牛a型产气荚膜梭菌灭活类毒素疫苗及其制备方法
CN120392991A (zh) * 2018-03-02 2025-08-01 一康合资有限公司 作为疫苗的来自产气荚膜梭菌的ε毒素
CN108578686B (zh) * 2018-04-23 2022-07-01 杨凌凯瑞生物科技有限公司 一种制备羊梭菌病基因工程亚单位疫苗的方法
CN109111509B (zh) * 2018-09-19 2021-08-13 天康制药(苏州)有限公司 腐败梭菌α毒素突变体、表达其的基因、制备方法和腐败梭菌疫苗
CN111500482B (zh) * 2019-01-31 2023-09-05 内蒙古金宇保灵生物技术研究院有限公司 一种羊a型产气荚膜梭菌菌株及其灭活疫苗和疫苗制备方法
CN109943507B (zh) * 2019-03-26 2021-08-17 中国兽医药品监察所 一种兽用a型产气荚膜梭菌类毒素的制备方法及其应用
CN110041437B (zh) * 2019-04-29 2020-12-25 中国兽医药品监察所 一种无毒性破伤风毒素和诺维梭菌α毒素重组融合蛋白
CN115477699A (zh) * 2022-10-14 2022-12-16 华中农业大学 抗产气荚膜梭菌卵黄抗体及其制备方法
CN118006636B (zh) * 2024-01-19 2025-12-30 扬州大学 一种鸡产气荚膜梭菌Mbp基因及其应用
CN120384029B (zh) * 2025-06-27 2025-10-28 国药集团动物保健股份有限公司 一株猪源a型产气荚膜梭菌及其在疫苗制备中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2257230B1 (es) 1973-09-14 1976-11-19 Agronomique Inst Nat Rech
SU627612A1 (ru) * 1977-09-30 1980-02-05 Zemlyakova V P Препарат земл ковой в.п. против клюстридиозов животных и птиц
MX9302964A (es) * 1992-05-20 1995-01-31 Secr Defence Vacunas de clostridium perfringens.
WO1994022476A1 (en) * 1993-03-29 1994-10-13 Pfizer Inc. Multicomponent clostridial vaccines using saponin adjuvants
US6048535A (en) 1997-06-12 2000-04-11 Regents Of The University Of Minnesota Multivalent in ovo avian vaccine
RU2129441C1 (ru) * 1997-12-10 1999-04-27 Пирожков Михаил Константинович Вакцина, ассоциированная против анаэробной энтеротоксемии и эшерихиоза поросят
CA2486618C (en) 2002-05-21 2013-04-09 Schering-Plough Ltd. Methods for the in vitro culture of sporozoea sp. and uses thereof
JP4771954B2 (ja) * 2003-06-09 2011-09-14 コリクサ コーポレーション Ｄｎａベクター
EP1654000A1 (en) * 2003-08-14 2006-05-10 Merial Limited Compositions and vaccines containing antigen(s) of cryptosporidium parvum and of another pathogen
WO2006041933A2 (en) * 2004-10-05 2006-04-20 Diversa Corporation Improved vaccines
MY149604A (en) * 2005-04-18 2013-09-13 Schering Plough Ltd C.perfringens alpha toxoid vaccine
MX2009005117A (es) 2006-11-20 2009-05-27 Intervet Int Bv Uso de bacteria clostridium perfringens de tipo c para la elaboracion de una vacuna.

Also Published As

Publication number Publication date
US9662380B2 (en) 2017-05-30
DK1874344T3 (en) 2016-09-19
BRPI0610843A2 (pt) 2010-07-27
MA29406B1 (fr) 2008-04-01
MY149604A (en) 2013-09-13
IL186701A0 (en) 2008-02-09
CA2606180C (en) 2016-09-13
CN101198352A (zh) 2008-06-11
WO2006113772A1 (en) 2006-10-26
UA98099C2 (uk) 2012-04-25
US20150140033A1 (en) 2015-05-21
RU2434638C2 (ru) 2011-11-27
AU2006236365A1 (en) 2006-10-26
US20060233825A1 (en) 2006-10-19
BRPI0610843B1 (pt) 2021-11-30
CR9443A (es) 2008-02-20
SG186672A1 (en) 2013-01-30
TNSN07387A1 (en) 2009-03-17
TWI311057B (en) 2009-06-21
AU2006236365B2 (en) 2012-02-02
EP1874344B1 (en) 2016-06-08
US8980283B2 (en) 2015-03-17
JP5243951B2 (ja) 2013-07-24
RU2007142337A (ru) 2009-05-27
NZ562637A (en) 2010-06-25
KR20080005277A (ko) 2008-01-10
JP2012062330A (ja) 2012-03-29
CA2606180A1 (en) 2006-10-26
ES2583484T3 (es) 2016-09-21
MX2007013053A (es) 2008-01-14
TW200719910A (en) 2007-06-01
PE20061398A1 (es) 2007-01-15
CN101198352B (zh) 2011-07-27
EP1874344A1 (en) 2008-01-09
ZA200709516B (en) 2008-11-26
JP2008536936A (ja) 2008-09-11

Similar Documents

Publication Publication Date Title
AR054251A1 (es) Vacuna de toxoide de c. perfringens alfa
CL2019003636A1 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson.
ECSP099079A (es) Mimeticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos
CR11122A (es) Vacuna de influenza de emulsion de aceite en agua
MX2018010586A (es) Nanovacuna de activacion de "sting" para inmunoterapia.
BRPI0509528A (pt) corpos imitação de glp-1 humana, composições, processos e usos
CR10726A (es) Vacuna que comprende un adyuvante de emulsion de aceite en agua
BRPI0509606A (pt) emulsões de óleo-em-água microfluidizadas e composições para vacinas
NI200700158A (es) Agonistas glp-1, composiciones, métodos y usos
BRPI0510430A (pt) composições e métodos para vacinação mucosal
CL2012003281A1 (es) Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
CR20130016A (es) ANTICUERPOS PEPTIDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
MA27047A1 (fr) Vaccination unidose avec mycoplasma hyopneumoniae.
AR025750A1 (es) Vacunas
BRPI0812856A2 (pt) Composições de vacina de emulsão que compreendem antígeno e adjuvante na fase aquosa.
AR060565A1 (es) Vacuna para la gripe aviaria y metodos de uso
PH12015501875A1 (en) Acellular pertussis vaccine
MX2016001695A (es) Composiciones inmunogenas de combinacion.
BR112014014973A2 (pt) preparações contendo emodepside amorfo
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
BRPI0508655A (pt) composição de vacina; método para a prevenção ou atenuação de erliquiose canina em um cão; e composição de estirpe desafiante
GT200500094A (es) Formulaciones liquidas administrables pro via dermica para combatir artropodos parasitos en animales
ECSP12011951A (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnóstico para una enfermedad parasitaria
ECSP12011892A (es) Combinación de fármacos con teobromina y su uso en terapia
HN2003000104A (es) Derivados de ciclopenteno

Legal Events

Date Code Title Description
FC Refusal